Literature DB >> 15496214

Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.

J Horn1.   

Abstract

Proton pump inhibitors are now considered the mainstay of treatment for acid-related disease. Although all proton pump inhibitors are highly effective, the antisecretory effects of different drugs in this class are not completely consistent across patients. One reason for this is the acid-suppressing effect of Helicobacter pylori infection, which may augment the actions of proton pump inhibitors. A second important reason for interpatient variability of the effects of proton pump inhibitors on acid secretion involves genetically determined differences in the metabolism of these drugs. This article focuses on the impact of genetic polymorphism of cytochrome P450 (CYP)2C19 on the pharmacokinetics and pharmacodynamics of proton pump inhibitors, particularly rabeprazole. Results reviewed indicate that the metabolism and pharmacokinetics of rabeprazole differ significantly from those of other proton pump inhibitors. Most importantly, the clearance of rabeprazole is largely nonenzymatic and less dependent on CYP2C19 than other drugs in its class. This results in greater consistency of pharmacokinetics for rabeprazole across a wide range of patients with acid-related disease, particularly those with different CYP2C19 genotypes. The pharmacodynamic profile for rabeprazole is also characterized by more rapid suppression of gastric acid secretion than with other proton pump inhibitors, which is also independent of CYP2C19 genotype. The favourable pharmacokinetic/pharmacodynamic profile for rabeprazole has been shown to result in high eradication rates for H. pylori in both normal and poor metabolizers. Pharmacodynamic results have also suggested that rabeprazole may be better suited than omeprazole as on-demand therapy for symptomatic gastro-oesophageal reflux disease. Finally, the use of rabeprazole is not complicated by clinically significant drug-drug interactions of the type that have been reported for omeprazole.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15496214     DOI: 10.1111/j.1365-2036.2004.02161.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  21 in total

1.  Comparative efficacy of rabeprazole and pantoprazole in the control of nocturnal Acid output and intragastric acidity.

Authors:  Hank S Wang; David S Oh; Ariana Anderson; Jose Nieto; Phuong Tien; Gordon Ohning; Joseph R Pisegna
Journal:  Gut Liver       Date:  2008-06-30       Impact factor: 4.519

2.  The chemically elegant proton pump inhibitors.

Authors:  Victoria F Roche
Journal:  Am J Pharm Educ       Date:  2006-10-15       Impact factor: 2.047

Review 3.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

4.  Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs).

Authors:  Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

Review 5.  Pharmacogenomics of antimicrobial agents.

Authors:  Ar Kar Aung; David W Haas; Todd Hulgan; Elizabeth J Phillips
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

6.  Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.

Authors:  Stanislas Bruley des Varannes; Sylvie Sacher-Huvelin; Fabienne Vavasseur; Claude Masliah; Marc Le Rhun; Philippe Aygalenq; Sylvie Bonnot-Marlier; Yves Lequeux; Jean Paul Galmiche
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

Review 7.  Genetic factors in the pathogenesis of gastroesophageal reflux disease.

Authors:  Uday C Ghoshal; Dipti Chourasia
Journal:  Indian J Gastroenterol       Date:  2011-05-12

8.  Rabeprazole combined with hydrotalcite is effective for patients with bile reflux gastritis after cholecystectomy.

Authors:  Huimin Chen; Xiaobo Li; Zhizheng Ge; Yunjie Gao; Xiaoyu Chen; Yun Cui
Journal:  Can J Gastroenterol       Date:  2010-03       Impact factor: 3.522

9.  Monitoring cytochrome P-450 activity during rabeprazole treatment in patients with gastresophageal reflux disease.

Authors:  Edoardo G Giannini; Vincenzo Savarino; Roberto Testa
Journal:  Dig Dis Sci       Date:  2006-08-22       Impact factor: 3.199

Review 10.  Proton pump inhibitors: impact on glucose metabolism.

Authors:  Diana Boj-Carceller
Journal:  Endocrine       Date:  2012-08-12       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.